ORIC Pharmaceuticals announced the appointments of Ashraf Hanna, PhD, MD, as Chief Executive Officer, and Darcy Mootz, PhD, as Chief Business Officer. Dr. Hanna will take over from Rich Heyman, PhD, who has been the interim CEO for the past six months. Prior to joining ORIC, Dr. Hanna was Vice President of Commercial and Medical Affairs Finance at Genentech and CFO of the Genentech Foundation.

He was a member of Genentech's Commercial Leadership Committee, and previously headed Genentech's Alliance Management and Portfolio Planning groups. Prior to joining ORIC, Dr. Mootz was Vice President of Corporate Development at Achaogen, where she led corporate development & alliance management, served as the project team leader for the company's lead asset, and contributed to successful financings, including an IPO.